Ascend Advanced Therapies, a purveyor in gene therapy development and partnership, has completed the strategic acquisition of a good manufacturing practice (GMP) facility in Alachua, Florida from Beacon Therapeutics. This move extends Ascend’s capabilities to support research through commercialization with a team steeped in gene therapy expertise. Mike Stella, CEO at Ascend, underscores the importance of consolidating both technology and seasoned talent in escalating the company’s comprehensive adeno-associated virus (AAV) platform. Ensuring supply for Beacon’s clinical products and concentrating on clinical development come forth as pivotal aspects of this new relationship. Beacon’s CEO, David Fellows, emphasizes the crucial role that Ascend’s manufacturing experience plays in advancing Beacon’s pipeline, including AGTC-501 for X-Linked Retinitis Pigmentosa treatment. The transaction enables a long-term union focused on growth and product quality, fortifying both parties in the competitive field of ocular gene therapy. Ascend’s acquisitional strategy remains robust, expanding its global network with recent developments in the San Francisco Bay Area, Munich, Germany, and now Alachua, Florida. This global presence equips Ascend with the expertise and infrastructure to offer end-to-end support for gene therapy clients. The transaction, closed on 1st April 2024, signals immediate integration efforts, representing a hallmark of Ascend’s rapid operational and strategic expansion embarked since its inception in 2023.
Biotechnology, Pharmaceutical Manufacturing, Healthcare & Pharmaceuticals,United States, Germany
https://www.synconaltd.com/news-and-insights/news/ascend-acquires-gmp-manufacturing-capacity-in-alachua-florida-enters-long-term-partnership-with-beacon-therapeutics-for-clinical-and-commercial-aav-production/